NanoViricides, Inc. — Form 8-K Summary
Business context and reporting period: The September 28, 2026 Form 8-K reports executive employment-agreement extensions. The agreements were entered into September 25 and are effective July 1, 2026. This filing does not report operating or period-end financial results.
Executive compensation and key terms
- President Anil R. Diwan: Extension through June 30, 2027, with an annual base salary of $400,000. The company granted him 10,204 shares of Series A preferred stock, vesting in equal quarterly installments from September 30, 2026 through June 30, 2027.
- The company will maintain a $2 million term-life insurance policy, with $1 million assigned to the company and the balance to Dr. Diwan’s estate. If terminated without cause, he is eligible for six months’ salary as severance and continued benefits during that period; payment may be a lump sum or installments.
- CFO Meeta Vyas: Extension for July 1, 2026 through June 30, 2027, renewable annually and otherwise on the same general terms as her prior agreement. The extension adds reimbursement for up to 50% of subscribed health-insurance costs, capped at $2,500 per month.
Changes versus prior terms
The filing extends both executives’ service agreements for one year. For Ms. Vyas, it specifically adds the health-insurance reimbursement provision. The filing describes her historical compensation as $10,800 per month in cash, following a 2015 increase, plus 129 Series A preferred shares monthly under the original agreement; it does not clearly state the current compensation amounts or award terms under the extension.
Financial impact, outlook, and risks
No revenue, profit, cash flow, margin, debt, liquidity, or financial guidance information is provided. The disclosed salary, equity award, insurance, reimbursement, and potential severance terms are compensation commitments; the filing does not quantify their total expense or cash-flow effect. No business outlook or other contingencies are discussed.
Important facts for investors to verify
- Review Exhibits 10.1 and 10.2 for the complete agreement terms, including any provisions not summarized in the 8-K.
- Confirm the rights and economic or voting features of the 10,204 Series A preferred shares and their vesting schedule.
- Clarify Ms. Vyas’s current cash and preferred-stock compensation under the extension, which the filing text does not clearly specify.
- Assess the company’s financial statements for the cost and funding implications of executive compensation and potential severance obligations.